| Globe & Mail (Toronto, Canada) 2001 Leonard Zehr |
| Title | Subject | Authors |
|---|
| Adherex makes plans to market IPO.(Adherex Technologies Inc.) | News, opinion and commentary | Leonard Zehr |
| Aventis cancer vaccine to begin trial.(Aventis Pasteur Ltd. ) | News, opinion and commentary | Leonard Zehr |
| Biomira shares jump 16%.(Biomira Inc., receives investment from Merck for cancer vaccines) | News, opinion and commentary | Leonard Zehr |
| Biotech bets on AIDS treatment kit. | News, opinion and commentary | Leonard Zehr |
| Biotech sector heating up.(QLT Inc. and Angiotech Pharmaceuticals Inc. are prime targets for acquisition) | News, opinion and commentary | Leonard Zehr |
| Biovail boss takes new tack on drugs.(Brief Article) | News, opinion and commentary | Leonard Zehr |
| Biovail building war chest.(Biovail Corp.; common share issue) | News, opinion and commentary | Leonard Zehr |
| Biovail buys rights to leading heart drug.(North American rights aquired fom Aventis) | News, opinion and commentary | Leonard Zehr |
| Biovail set to double sales staff next year.(Biovail Corp. will hire 500 additional sales representatives)(International Pages) | News, opinion and commentary | Leonard Zehr |
| Biovail shares hit 52-week high (Biovail Corp., reports strong earnings). | News, opinion and commentary | Leonard Zehr |
| Celmed launched to develop cell R&D.(Celmed Biosciences Inc.) | News, opinion and commentary | Leonard Zehr |
| Despite slumping profit, BioChem tops expectations. | News, opinion and commentary | Leonard Zehr |
| Dimethaid lines up $50-million credit line.(Deal first equity financing by Acqua with Canadian firm.) | News, opinion and commentary | Leonard Zehr |
| Drug approvals seen slowing.(U.S. Food and Drug Administration halts Hemolink product)(Government Activity)(International Pages) | News, opinion and commentary | Leonard Zehr |
| Generic drugs will fuel revenue, Biovail chief says.(Eugene Melnyk) | News, opinion and commentary | Leonard Zehr |
| Icon Laser Eye makes bid for Lasik Vision.(Offers $24-million in stock for rival to consolidate laser eye surgery business.) | News, opinion and commentary | Leonard Zehr |
| Icon Laser to sell Europe unit.(Icon Laser Eye Centers Inc. )(Brief Article) | News, opinion and commentary | Leonard Zehr |
| Icon to appeal Lasik Vision decision.(Icon Laser Eye Centers Inc.) | News, opinion and commentary | Leonard Zehr |
| Icon to appeal Lasik Vision decision.(Icon Laser Eye Centers Inc.) | News, opinion and commentary | Leonard Zehr |
| IMI seeks FDA approval on skin test.(IMI International Medical Innovations Inc. ) | News, opinion and commentary | Leonard Zehr |
| Investors bail out of MDS warrants.(MDS Proteomics Inc.) | News, opinion and commentary | Leonard Zehr |
| Jamieson looks south to swallow much bigger pill.(Jamieson Laboratories Ltd. )(Brief Article) | News, opinion and commentary | Leonard Zehr |
| KS Biomedix boosts reach with purchase of Avincenna.(KS Biomedix Holdings PLC and Avicenna Medica Inc.) | News, opinion and commentary | Leonard Zehr |
| Laser eye surgery giants to merge.(TLC Laser Eye Centers Inc. and Laser Vision Centers Inc.) | News, opinion and commentary | Leonard Zehr |
| Lasik Vision petitioned into bankruptcy. | News, opinion and commentary | Leonard Zehr |
| MDS unit gears up to revive aborted offering.(MDS Proteomics Inc.) | News, opinion and commentary | Leonard Zehr |
| Oncolytics Biotech rises on cancer virus news. | News, opinion and commentary | Leonard Zehr |
| Ottawa approves biotech deal as probe launched.(BioChem Pharma-Shire Pharmaceutical merger) | News, opinion and commentary | Leonard Zehr |
| Partners' dispute hits Angiotech shares. | News, opinion and commentary | Leonard Zehr |
| Patheon shares deflate on flat forecast.(Patheon Inc.) | News, opinion and commentary | Leonard Zehr |
| QLT names new CEO.(QLT Inc. appoints Paul Hastings as new CEO)(Abstract) | News, opinion and commentary | Leonard Zehr |
| QLT paid executives U.S. cash equivalent, raising salaries 40%.(QLT Inc. readies blindness treatment drug) | News, opinion and commentary | Leonard Zehr |
| QLT profit jumps in third quarter.(QLT Inc.)(Company Profile) | News, opinion and commentary | Leonard Zehr |
| TD Securities buys into equity options sector.(acquires two Chicago-based dealers) | News, opinion and commentary | Leonard Zehr |
| The brains behind SignalGene.(Michael Dennis is credited with the biotech's rebound.) | News, opinion and commentary | Leonard Zehr |
| The Monday interview: Lucas has prescription for drug firm mergers.(Boss (Paul Lucas) of GlaxoSmithKline's Canadian arm sets corporate culture as a strategic goal.)(Interview) | News, opinion and commentary | Leonard Zehr |
| TLC Laser trims loss by cutting expenses.(TLC Laser Eye Centers Inc.) | News, opinion and commentary | Leonard Zehr |
| TLC writing down investment.(TLC Laser Eye Centers Inc. takes writedown of between $17 mn and $20 mn)(International Pages) | News, opinion and commentary | Leonard Zehr |
| Two Icon Laser top executives step down.(Icon Laser Eye Centers Inc.'s president, Ghassan Barazi and CEO, Ernest Remo ) | News, opinion and commentary | Leonard Zehr |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
